These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 20001553

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. P21-activated kinase is required for mitotic progression and regulates Plk1.
    Maroto B, Ye MB, von Lohneysen K, Schnelzer A, Knaus UG.
    Oncogene; 2008 Aug 21; 27(36):4900-8. PubMed ID: 18427546
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
    Johnson EF, Stewart KD, Woods KW, Giranda VL, Luo Y.
    Biochemistry; 2007 Aug 21; 46(33):9551-63. PubMed ID: 17655330
    [Abstract] [Full Text] [Related]

  • 28. Structure of the catalytic domain of human polo-like kinase 1.
    Kothe M, Kohls D, Low S, Coli R, Cheng AC, Jacques SL, Johnson TL, Lewis C, Loh C, Nonomiya J, Sheils AL, Verdries KA, Wynn TA, Kuhn C, Ding YH.
    Biochemistry; 2007 May 22; 46(20):5960-71. PubMed ID: 17461553
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
    Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, Gürtler U, Garin-Chesa P, Lieb S, Quant J, Grauert M, Adolf GR, Kraut N, Peters JM, Rettig WJ.
    Curr Biol; 2007 Feb 20; 17(4):316-22. PubMed ID: 17291758
    [Abstract] [Full Text] [Related]

  • 32. Polo-like kinase (Plk) 1 as a target for prostate cancer management.
    Reagan-Shaw S, Ahmad N.
    IUBMB Life; 2005 Oct 20; 57(10):677-82. PubMed ID: 16223707
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies.
    Ikezoe T, Yang J, Nishioka C, Takezaki Y, Tasaka T, Togitani K, Koeffler HP, Yokoyama A.
    Leukemia; 2009 Sep 20; 23(9):1564-76. PubMed ID: 19421227
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.
    Maire V, Némati F, Richardson M, Vincent-Salomon A, Tesson B, Rigaill G, Gravier E, Marty-Prouvost B, De Koning L, Lang G, Gentien D, Dumont A, Barillot E, Marangoni E, Decaudin D, Roman-Roman S, Pierré A, Cruzalegui F, Depil S, Tucker GC, Dubois T.
    Cancer Res; 2013 Jan 15; 73(2):813-23. PubMed ID: 23144294
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
    Kreis NN, Louwen F, Zimmer B, Yuan J.
    Oncotarget; 2015 Mar 30; 6(9):6611-26. PubMed ID: 25483104
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.